Use of platinum-based chemotherapy

Use of platinum-based chemotherapy doublets is the standard
of care for patients with advanced-stage non–small cell lung cancer, being
associated with improved survival compared with best supportive care in
fit patients with good performance status. Randomized studies showed that
the addition of monoclonal antibodies against vascular endothelial growth
factor receptor or epidermal growth factor receptor may increase the survival
compared to chemotherapy alone. Patients with either advanced age
or poor performance status can also benefit from chemotherapy. Docetaxel
with or without ramucirumab, pemetrexed, and erlotinib are approved for
previously treated patients. New treatment approaches are needed to improve
the outcomes in this patient population.

結果 (中文) 1:

使用铂为基础的化疗双峰是标准高级阶段 — — 非小细胞肺癌病人照顾被关联与提高生存率与最佳支持治疗相比适合患者具有良好的性能状态。随机的研究表明，抗血管内皮生长单克隆抗体的加法因子受体或表皮生长因子受体可能提高生存率相比单纯化疗。要么高龄患者或表现不佳状态也从化疗中获益。多西紫杉醇不管有没有 ramucirumab，培美曲塞和埃罗替尼被核准为以前治疗的患者。新的治疗方法，以提高结果该患者群体。

結果 (中文) 3:

为基础的化疗对铂的使用是治疗晚期非小细胞肺癌患者–标准
，被
与最佳支持治疗
适合具有良好的性能状态的患者相比生存改善相关。随机研究表明，抗血管内皮细胞生长因子的单克隆抗体的加入因子受体或表皮生长因子受体可能会增加生存相比，单纯化疗。无论是高龄者，或表现欠佳的患者，也能从化疗中获益。多西他赛
或不治疗，培美曲塞，厄洛替尼和批准
以前治疗的患者。需要新的治疗方法来改善the Outcomes in this病人的人口。